San Diego based OncoSec Medical Incorporated has announced that Investigational Review Board (IRB) approval has been received by the University of California San Francisco and that the first patient has been dosed for a Phase II clinical trial evaluating the safety and efficacy of OncoSec's OMS ElectroImmunotherapy for the treatment of advanced stage cutaneous and in-transit metastatic melanoma.
OncoSec is aiming to recruit 25 patients for this Phase II study who have been diagnosed with stage III or stage IV cutaneous and in-transit metastatic melanoma.
OMS ElectroImmunotherapy is a proprietary technology that delivers a DNA-based drug coded for the immune stimulating agent interleukin-12 (also known as DNA IL-12). Short electrical pulses are then delivered to the tumor, allowing for greater uptake of the interleukin.
Source: Therapeutics Daily
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
